All patients

(N = 172)

N (%)

2000-2005

(N = 47)

N (%)

2006-2011

(N = 125)

N (%)

Age at any metastases diagnosis

52 (24 - 87)

50 (27 -6 8)

52 (24 - 87)

Age at CNS metastases

53 (24 - 87)

51 (28 - 68)

52 (24 - 87)

Race/ethnicity n (%)

White

Hispanic

AA

Asian

Missing

80 (46.5)

44 (25.6)

12 (7)

28 (16.2)

8 (4.7)

23 (48.9)

12 (25.5)

5 (10.6)

7 (15)

54 (43.2)

35 (28)

7 (5.6)

21 (16.8)

8 (6.4)

Marital Status

Married

Single

Divorced/separated

Widowed

Unknown

110 (63.9)

18 (10.5)

22 (12.8)

13 (7.6)

9 (5.2)

42 (89.4)

4 (8.5)

1 (2.1)

74 (59.2)

14 (11.2)

16 (12.8)

13 (10.4)

8 (6.4)

CNS mets diagnosis

De novo

Progression

Missing

25 (14.5)

139 (80.8)

8 (4.7)

4 (8.5)

43 (91.5)

21 (16.8)

96 (76.8)

8 (16.4)

Type

Leptomeningeal

Brain lesions

17 (10)

155 (90)

1 (2.1)

46 (97.9)

16 (12.8)

109 (87.2)

Extracranial metastases site

Lung

Liver

Bone

Skin

Multiple sites

3 (1.7)

2 (1.2)

26 (15.1)

2 (1.2)

139 (80.8)

2 (4.2)

2 (4.2)

8 (17)

1 (2.1)

34 (72.5)

1 (0.8)

18 (14.4)

1 (0.8)

105 (84)

ER

Negative

Positive

Unknown

79 (45.9)

84 (48.8)

9 (5.3)

20 (42.5)

20 (42.5)

7 (15)

59 (47.2)

64 (51.2)

2 (1.6)

PR

Negative

Positive

Unknown

103 (59.9)

59 (34.3)

10 (5.8)

27 (57.4)

13 (27.7)

7 (14.9)

76 (60.8)

46 (36.8)

3 (2.4)

HER2

Negative

Borderline

Positive

Unknown

90 (52.3)

2 (1.2)

66 (38.4)

14 (8.1)

21 (44.7)

1 (2.1)

16 (34)

9 (19.2)

69 (55.2)

1 (0.8)

50 (40)

5 (4)

Histology

Ductal

Metaplastic

Lobular

Nos

Inflammatory

Mixed

Missing

114 (66.3)

1 (0.6)

8 (4.7)

12 (6.9)

18 (10.5)

9 (5.2)

10 (5.8)

30 (63.8)

1 (2.1)

4 (8.6)

11 (23.4)

1 (2.1)

84 (67.2)

1 (0.8)

7 (5.6)

8 (6.4)

7 (5.6)

8 (6.4)

10 (8)